Silence Therapeutics plc
SLNHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeSilence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of. Valued at $496.0M, SLN is a small-cap name in its sector. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases.
Market Cap
$496.0M
Beta
1.38
P/E (TTM)
—
P/E (Fwd)
-26.92
EPS (TTM)
$-1.56
EPS (Fwd)
$-0.39
ROE
-92.6%
ROA
-29.8%
Cash
$70.1M
Total Debt
$136,000
Free CF
-$45.7M
52W Change
73.8%
Annual Financials
Cash vs Debt
The balance sheet looks solid with $70.1M in cash comfortably exceeding the $136K debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$45.7M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -92.6% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has been uneven over recent years, ranging from $21.7M to $559K.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. No single metric tells the full story. Reviewing SLN's risk profile alongside its fundamentals and technical indicators provides a more complete picture.